180 Life Sciences (180 Life Sciences) Retained Earnings : $-128.41 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. 180 Life Sciences's retained earnings for the quarter that ended in Mar. 2024 was $-128.41 Mil.

180 Life Sciences's quarterly retained earnings declined from Sep. 2023 ($-126.12 Mil) to Dec. 2023 ($-127.34 Mil) and declined from Dec. 2023 ($-127.34 Mil) to Mar. 2024 ($-128.41 Mil).

180 Life Sciences's annual retained earnings declined from Dec. 2021 ($-68.68 Mil) to Dec. 2022 ($-107.41 Mil) and declined from Dec. 2022 ($-107.41 Mil) to Dec. 2023 ($-127.34 Mil).

180 Life Sciences Retained Earnings Historical Data

The historical data trend for 180 Life Sciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences Retained Earnings Chart

180 Life Sciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

-37.47

-48.36

-68.68

-107.41

-127.34

180 Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-112.17	-115.85	-126.12	-127.34	-128.41

180 Life Sciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

180 Life Sciences (NAS:ATNF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

180 Life Sciences (180 Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306

Website

https://www.180lifesciences.com

180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.

Executives

James N. Woody	director, officer: Chief Executive Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann	director	5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A.	director	C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu	officer: COO / Chief Business Officer	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir	officer: Interim CFO	2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone	director	C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca	director	40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis	director	205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss	director, 10 percent owner, officer: Chief Executive Officer	C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold	director	830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard	officer: Chief Scientific Officer	501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker	director	290 COMMONWEALTH AVENUE #17, BOSTON MA 02115